These hydrolyze ATP, which is released by chemotherapy-treated tumor cells, into adenosine and attenuate chemotherapeutic efficacy by constraining CD8+ T cell responses in melanoma, as well as colon and breast cancer models in vitro and in vivo. This evidence concerns the gene CD8A and neoplasm.